As regards the relationship between immunophenotype and prognosis, the best outcomes have been observed in the cortical T-cell ALL, while CD1a-negative patients show an increased relapse rate and a lower survival (7, 8). This evidence concerns the gene CD1A and acute lymphoblastic leukemia.